Free Trial

OptiBiotix Health (OPTI) Competitors

GBX 24
+2.25 (+10.34%)
(As of 07/19/2024 ET)

OPTI vs. POLB, ORPH, REDX, ETX, TRX, SAR, AREC, MTPH, COS, and C4XD

Should you be buying OptiBiotix Health stock or one of its competitors? The main competitors of OptiBiotix Health include Poolbeg Pharma (POLB), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Sareum (SAR), Arecor Therapeutics (AREC), Biodexa Pharmaceuticals (MTPH), Collagen Solutions plc (COS.L) (COS), and C4X Discovery (C4XD). These companies are all part of the "biotechnology" industry.

OptiBiotix Health vs.

Poolbeg Pharma (LON:POLB) and OptiBiotix Health (LON:OPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, community ranking, profitability, earnings, dividends and risk.

6.1% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 5.9% of OptiBiotix Health shares are held by institutional investors. 22.7% of Poolbeg Pharma shares are held by company insiders. Comparatively, 12.5% of OptiBiotix Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Poolbeg Pharma has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, OptiBiotix Health has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.

In the previous week, OptiBiotix Health had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for OptiBiotix Health and 0 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.34 beat OptiBiotix Health's score of 0.00 indicating that OptiBiotix Health is being referred to more favorably in the news media.

Company Overall Sentiment
Poolbeg Pharma Neutral
OptiBiotix Health Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Poolbeg Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
OptiBiotix Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Poolbeg Pharma has higher earnings, but lower revenue than OptiBiotix Health. Poolbeg Pharma is trading at a lower price-to-earnings ratio than OptiBiotix Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£3.93M-£0.01-1,290.00
OptiBiotix Health£1.26M18.66-£13.18M-£0.15-160.00

OptiBiotix Health's return on equity of -24.00% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -24.00% -18.14%
OptiBiotix Health N/A -85.52%-8.50%

OptiBiotix Health received 145 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.

CompanyUnderperformOutperform
Poolbeg PharmaN/AN/A
OptiBiotix HealthOutperform Votes
145
59.18%
Underperform Votes
100
40.82%

Summary

Poolbeg Pharma and OptiBiotix Health tied by winning 6 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPTI vs. The Competition

MetricOptiBiotix HealthBiotechnology IndustryMedical SectorLON Exchange
Market Cap£23.51M£136.90M£5.40B£1.50B
Dividend YieldN/A3.49%2.81%11.82%
P/E Ratio-160.00253.87168.951,809.64
Price / Sales18.6617,976.232,174.24327,096.40
Price / Cash8.6811.8436.2434.51
Price / Book2.406.634.862.78
Net Income-£13.18M-£19.20M£111.24M£155.97M
7 Day Performance-2.04%-0.36%-0.71%0.24%
1 Month Performance47.69%1.55%6.92%1.13%
1 Year Performance104.26%8.65%3.90%95.46%

OptiBiotix Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POLB
Poolbeg Pharma
0 of 5 stars
0.00 / 5 stars
GBX 13.45
flat
N/A+77.0%£67.25MN/A-1,345.0012
ORPH
Open Orphan
0 of 5 stars
0.00 / 5 stars
GBX 10
+5.3%
N/A+0.0%£67.09M£34.71M-25.30179News Coverage
REDX
Redx Pharma
0 of 5 stars
0.00 / 5 stars
GBX 15
+31.6%
N/A-41.2%£58.35M£4.20M-150.00101Gap Up
High Trading Volume
ETX
e-therapeutics
0 of 5 stars
0.00 / 5 stars
GBX 9
-6.7%
N/A-52.6%£52.59M£295,000.00-450.0034High Trading Volume
TRX
Tissue Regenix Group
0 of 5 stars
0.00 / 5 stars
GBX 72.10
-2.6%
N/A+21.8%£50.88M£29.49M-3,605.0082News Coverage
SAR
Sareum
0 of 5 stars
0.00 / 5 stars
GBX 35.80
+0.8%
N/A-65.0%£38.65M£47,204.00-596.673,211
AREC
Arecor Therapeutics
0 of 5 stars
0.00 / 5 stars
GBX 103.50
+1.3%
N/A-53.8%£31.70M£4.57M-506.6551Gap Down
MTPH
Biodexa Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
GBX 18
+1,794.7%
N/A+0.0%£31.20M£645,000.00-21.9518Gap Up
COS
Collagen Solutions plc (COS.L)
0 of 5 stars
0.00 / 5 stars
GBX 6.63
flat
N/AN/A£30.99M£4.01M-8.2848
C4XD
C4X Discovery
0 of 5 stars
0.00 / 5 stars
GBX 12
+27.3%
N/A-40.0%£30.27M£24.68M300.0049News Coverage
High Trading Volume

Related Companies and Tools

This page (LON:OPTI) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners